User login
Key clinical point: Quarterly treatment with OnabotulinumtoxinA (BoNT-A) up to 4 years can provide long-lasting prevention of chronic migraine in real-life settings.
Main finding: From baseline to 48 months, there was a significant reduction in the mean number of monthly headache days and hours, consumption of analgesics, and latency time (P less than .001 for all). With repeated BoNT-A treatment, a progressive shift toward lower degrees of disability was seen at each subsequent timepoint (P less than .001 for trend). Six patients experienced transitory neck pain.
Study details: The data come from a retrospective real-life study of patients with chronic migraine who received quarterly treatment with BoNT-A up to 16 cycles (n = 109).
Disclosures: The authors declared no conflict of interest.
Citation: Santoro A et al. Neurol Sci. 2020 Feb 12. doi: 10.1007/s10072-020-04283-y.
Key clinical point: Quarterly treatment with OnabotulinumtoxinA (BoNT-A) up to 4 years can provide long-lasting prevention of chronic migraine in real-life settings.
Main finding: From baseline to 48 months, there was a significant reduction in the mean number of monthly headache days and hours, consumption of analgesics, and latency time (P less than .001 for all). With repeated BoNT-A treatment, a progressive shift toward lower degrees of disability was seen at each subsequent timepoint (P less than .001 for trend). Six patients experienced transitory neck pain.
Study details: The data come from a retrospective real-life study of patients with chronic migraine who received quarterly treatment with BoNT-A up to 16 cycles (n = 109).
Disclosures: The authors declared no conflict of interest.
Citation: Santoro A et al. Neurol Sci. 2020 Feb 12. doi: 10.1007/s10072-020-04283-y.
Key clinical point: Quarterly treatment with OnabotulinumtoxinA (BoNT-A) up to 4 years can provide long-lasting prevention of chronic migraine in real-life settings.
Main finding: From baseline to 48 months, there was a significant reduction in the mean number of monthly headache days and hours, consumption of analgesics, and latency time (P less than .001 for all). With repeated BoNT-A treatment, a progressive shift toward lower degrees of disability was seen at each subsequent timepoint (P less than .001 for trend). Six patients experienced transitory neck pain.
Study details: The data come from a retrospective real-life study of patients with chronic migraine who received quarterly treatment with BoNT-A up to 16 cycles (n = 109).
Disclosures: The authors declared no conflict of interest.
Citation: Santoro A et al. Neurol Sci. 2020 Feb 12. doi: 10.1007/s10072-020-04283-y.